The news is the latest example of the biotech industry's struggles in the Bay Area.

One of the world’s largest biotech companies is closing its only office in the Bay Area. Pfizer is shutting down its office ...

Pfizer is facing patent cliffs on multiple drugs in the next few years. The company has been making big acquisitions to ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. But the companies still plan to file the vaccine with regulators.

Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug program. But for Valneva CEO Thomas Lingelbach, the regulatory future of the ...

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, a lackluster result as fewer-than-expected infections in the pivotal study made its potency ...

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease, but the company could see pushback from the government following studies done on the vaccine. "What ...

Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, ...